Efficacy, Safety, and Acceptability of Mifepristone 50 mg Once-weekly as a Contraceptive

PHASE3RecruitingINTERVENTIONAL
Enrollment

1,186

Participants

Timeline

Start Date

May 2, 2025

Primary Completion Date

April 30, 2029

Study Completion Date

April 30, 2030

Conditions
Female Contraception
Interventions
DRUG

Mifepristone 50 mg

Once-weekly oral mifepristone 50 mg

Trial Locations (14)

1815 JD

RECRUITING

Noordwest Ziekenhuisgroep, Alkmaar

7609 PP

NOT_YET_RECRUITING

Ziekenhuisgroep Twente, Almelo

1315 RA

NOT_YET_RECRUITING

Flevoziekenhuis, Almere Stad

1105 AZ

NOT_YET_RECRUITING

Amsterdam Universitair Medische Centra, Amsterdam

7512 KZ

RECRUITING

Medisch Spectrum Twente, Enschede

4462 RA

RECRUITING

Admiraal De Ruyter Ziekenhuis, Goes

9728 NZ

RECRUITING

Martini Ziekenhuis, Groningen

8934 AD

RECRUITING

Medisch Centrum Leeuwarden, Leeuwarden

2333 ZA

RECRUITING

Leiden University Medical Center, Leiden

6229 HX

NOT_YET_RECRUITING

Maastricht Universitair Medisch Centrum, Maastricht

6532 SZ

NOT_YET_RECRUITING

Canisius Wilhelmina Ziekenhuis, Nijmegen

3045 PM

RECRUITING

Franciscus Gasthuis, Rotterdam

3582 KE

NOT_YET_RECRUITING

Diakonessenhuis, Utrecht

5504 DB

RECRUITING

Maxima Medisch Centrum, Veldhoven

All Listed Sponsors
collaborator

Karolinska Institutet

OTHER

collaborator

Women on Waves

UNKNOWN

collaborator

Children's Investment Fund Foundation

OTHER

lead

Leiden University Medical Center

OTHER